FIELD: biotechnology.
SUBSTANCE: described is a group of inventions involving the use of a bispecific antigen-binding molecule to CD3/MUC16 and 4-1BB agonist for treating MUC16-positive cancer or inhibiting the growth of MUC16-positive tumour and a pharmaceutical combination for treating MUC16-positive cancer or inhibiting the growth of MUC16-positive tumour. In one embodiment, the bispecific antigen-binding molecule to CD3/MUC16 contains the heavy chain variable region amino acid sequence SEQ ID NO: 1 and light chain variable region SEQ ID NO: 3.
EFFECT: invention extends the range of products for treating MUC16-positive cancer.
24 cl, 6 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND PSMA AND CD3, IN COMBINATION WITH COSTIMULATION 4-1BB | 2020 |
|
RU2822092C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2790288C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
| NEW PSMA-BINDING ANTIBODY AND ITS APPLICATIONS | 2017 |
|
RU2762704C2 |
| ANTIBODIES BINDING TO HLA-A2/WT1 | 2018 |
|
RU2815176C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
